Zydus receives final approval from USFDA for Clobetasol Propionate Ointment USP

Zydus Cadila has received final approval from the United States Food and Drug Administration (USFDA) to market Clobetasol Propionate Ointment USP, 0.05 percent.

October 30, 2017 / 12:49 IST

26 Aug, 2025 12:21

Volume

Todays L/H

Zydus Cadila has received final approval from the United States Food and Drug Administration (USFDA) to market Clobetasol Propionate Ointment USP, 0.05 percent.

At 12:42 hrs Cadila Healthcare was quoting at Rs 493.95, up Rs 2.55, or 0.52 percent.

The share touched its 52-week high Rs 558.00 and 52-week low Rs 342.00 on 12 June, 2017 and 26 December, 2016, respectively.

Currently, it is trading 11.48 percent below its 52-week high and 44.43 percent above its 52-week low.

Market capitalisation stands at Rs 50,567.77 crore.
Source : BSE

first published: Oct 30, 2017 12:49 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

Al Edge Newsletter On Saturdays

Find the best of Al News in one place, specially curated for you every weekend.
MC Tech 3 Newsletter Daily-Weekdays

Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347